MedPath

Cytos Biotechnology AG

🇨🇭Switzerland
Ownership
Private, Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

36

Active:18
Completed:16

Trial Phases

2 Phases

Phase 1:6
Phase 2:12

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials

Phase 2
12 (66.7%)
Phase 1
6 (33.3%)

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Phase 2
Withdrawn
Conditions
Asthma
First Posted Date
2014-03-14
Last Posted Date
2014-05-14
Lead Sponsor
Cytos Biotechnology AG
Registration Number
NCT02087644
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Phase 2
Terminated
Conditions
Moderate to Severe Allergic Asthma
First Posted Date
2012-08-28
Last Posted Date
2014-05-14
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
365
Registration Number
NCT01673672
Locations
🇺🇦

Cytos Investigator Sites, Vinnytsya, Ivano-Frankivsk, Ukraine

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2009-06-18
Last Posted Date
2012-02-13
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
48
Registration Number
NCT00924105
Locations
🇨🇭

Cytos Investigator sites, Zuerich, Switzerland

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Phase 2
Completed
Conditions
Allergic Bronchial Asthma
Interventions
Drug: Placebo
First Posted Date
2009-04-30
Last Posted Date
2012-02-13
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
63
Registration Number
NCT00890734
Locations
🇩🇪

Cytos Investigator Sites, Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Phase 2
Completed
Conditions
Rhinoconjunctivitis
Allergies
Interventions
Drug: Placebo
First Posted Date
2008-12-02
Last Posted Date
2010-11-15
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
300
Registration Number
NCT00800332
Locations
🇷🇴

Cytos Investigator Sites, Targu Mures, Bukarest, Craiova, Iasi, Romania

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.